
Pfizer Inc. (NYSE: PFE) Stock Competitors & Peer Comparison
See PFE's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PFE and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PFE | $28.89 | +0.21% | 164.7B | 9.47 | $3.05 | +5.96% |
| LLY | $1,443.50 | +1.26% | 1.4T | 45.90 | $31.49 | +0.48% |
| JNJ | $285.75 | +0.79% | 688.8B | 26.66 | $10.73 | +1.84% |
| ABBV | $295.03 | +0.20% | 521.6B | 28.96 | $10.19 | +2.34% |
| MRK | $147.76 | +0.55% | 364.3B | 46.03 | $3.21 | +2.30% |
| NVS | $160.50 | +0.16% | 303.2B | 18.47 | $8.69 | +2.95% |
| AZN | $184.45 | +0.04% | 286.1B | 19.92 | $9.26 | +1.75% |
| AMGN | $465.67 | -0.30% | 251.9B | 20.82 | $22.37 | +2.13% |
| GILD | $168.08 | +0.08% | 208.5B | -430.97 | -$0.39 | +1.93% |
| NVO | $41.63 | +2.41% | 184.5B | 10.36 | $4.02 | +4.31% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
PFE vs LLY Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, LLY has a market cap of 1.4T. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while LLY trades at $1,443.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas LLY's P/E ratio is 45.90. In terms of profitability, PFE's ROE is +0.05%, compared to LLY's ROE of +0.84%. Regarding short-term risk, PFE is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for PFE.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
PFE vs JNJ Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, JNJ has a market cap of 688.8B. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while JNJ trades at $285.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas JNJ's P/E ratio is 26.66. In terms of profitability, PFE's ROE is +0.05%, compared to JNJ's ROE of +0.20%. Regarding short-term risk, PFE is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for PFE.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
PFE vs ABBV Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, ABBV has a market cap of 521.6B. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while ABBV trades at $295.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas ABBV's P/E ratio is 28.96. In terms of profitability, PFE's ROE is +0.05%, compared to ABBV's ROE of -2.02%. Regarding short-term risk, PFE is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for PFE.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
PFE vs MRK Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, MRK has a market cap of 364.3B. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while MRK trades at $147.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas MRK's P/E ratio is 46.03. In terms of profitability, PFE's ROE is +0.05%, compared to MRK's ROE of +0.05%. Regarding short-term risk, PFE is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for PFE.Check MRK's competition here
Novartis AG (NYSE: NVS)
PFE vs NVS Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, NVS has a market cap of 303.2B. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while NVS trades at $160.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas NVS's P/E ratio is 18.47. In terms of profitability, PFE's ROE is +0.05%, compared to NVS's ROE of +0.25%. Regarding short-term risk, PFE is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for PFE.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
PFE vs AZN Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, AZN has a market cap of 286.1B. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while AZN trades at $184.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas AZN's P/E ratio is 19.92. In terms of profitability, PFE's ROE is +0.05%, compared to AZN's ROE of +0.22%. Regarding short-term risk, PFE is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for PFE.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
PFE vs AMGN Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, AMGN has a market cap of 251.9B. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while AMGN trades at $465.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas AMGN's P/E ratio is 20.82. In terms of profitability, PFE's ROE is +0.05%, compared to AMGN's ROE of +0.86%. Regarding short-term risk, PFE is more volatile compared to AMGN. This indicates higher risk in terms of short-term price fluctuations for PFE.Check AMGN's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
PFE vs GILD Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, GILD has a market cap of 208.5B. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while GILD trades at $168.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas GILD's P/E ratio is -430.97. In terms of profitability, PFE's ROE is +0.05%, compared to GILD's ROE of -0.22%. Regarding short-term risk, PFE is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for PFE.Check GILD's competition here
Novo Nordisk A/S (NYSE: NVO)
PFE vs NVO Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, NVO has a market cap of 184.5B. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while NVO trades at $41.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas NVO's P/E ratio is 10.36. In terms of profitability, PFE's ROE is +0.05%, compared to NVO's ROE of +0.54%. Regarding short-term risk, PFE is less volatile compared to NVO. This indicates lower risk in terms of short-term price fluctuations for PFE.Check NVO's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
PFE vs CELG-RI Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, CELG-RI has a market cap of 136.4B. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, PFE's ROE is +0.05%, compared to CELG-RI's ROE of +0.44%. Regarding short-term risk, PFE is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for PFE.Check CELG-RI's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
PFE vs BMY Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, BMY has a market cap of 129.6B. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while BMY trades at $63.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas BMY's P/E ratio is 10.69. In terms of profitability, PFE's ROE is +0.05%, compared to BMY's ROE of +0.44%. Regarding short-term risk, PFE is less volatile compared to BMY. This indicates lower risk in terms of short-term price fluctuations for PFE.Check BMY's competition here
Sanofi (NASDAQ: SNY)
PFE vs SNY Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, SNY has a market cap of 115.9B. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while SNY trades at $48.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas SNY's P/E ratio is 10.54. In terms of profitability, PFE's ROE is +0.05%, compared to SNY's ROE of +0.06%. Regarding short-term risk, PFE is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for PFE.Check SNY's competition here
GSK plc (NYSE: GSK)
PFE vs GSK Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, GSK has a market cap of 102.2B. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while GSK trades at $50.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas GSK's P/E ratio is 10.90. In terms of profitability, PFE's ROE is +0.05%, compared to GSK's ROE of +0.23%. Regarding short-term risk, PFE is less volatile compared to GSK. This indicates lower risk in terms of short-term price fluctuations for PFE.Check GSK's competition here
Biogen Inc. (NASDAQ: BIIB)
PFE vs BIIB Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, BIIB has a market cap of 37.5B. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while BIIB trades at $253.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas BIIB's P/E ratio is 16.00. In terms of profitability, PFE's ROE is +0.05%, compared to BIIB's ROE of +0.02%. Regarding short-term risk, PFE is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for PFE.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
PFE vs HZNP Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas HZNP's P/E ratio is 61.86. In terms of profitability, PFE's ROE is +0.05%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, PFE is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for PFE.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
PFE vs GRFS Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, GRFS has a market cap of 7.4B. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while GRFS trades at $8.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas GRFS's P/E ratio is 9.98. In terms of profitability, PFE's ROE is +0.05%, compared to GRFS's ROE of +0.09%. Regarding short-term risk, PFE is less volatile compared to GRFS. This indicates lower risk in terms of short-term price fluctuations for PFE.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
PFE vs OGN Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, OGN has a market cap of 3.7B. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while OGN trades at $13.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas OGN's P/E ratio is 4.15. In terms of profitability, PFE's ROE is +0.05%, compared to OGN's ROE of +0.22%. Regarding short-term risk, PFE is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for PFE.Check OGN's competition here
Amarin Corporation plc (NASDAQ: AMRN)
PFE vs AMRN Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, AMRN has a market cap of 235.4M. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while AMRN trades at $11.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas AMRN's P/E ratio is -113.80. In terms of profitability, PFE's ROE is +0.05%, compared to AMRN's ROE of -0.04%. Regarding short-term risk, PFE is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for PFE.Check AMRN's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
PFE vs MIRA Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, MIRA has a market cap of 27.7M. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while MIRA trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas MIRA's P/E ratio is -0.46. In terms of profitability, PFE's ROE is +0.05%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, PFE is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for PFE.Check MIRA's competition here
Scilex Holding Company (NASDAQ: SCLX)
PFE vs SCLX Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, SCLX has a market cap of 10.1M. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while SCLX trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas SCLX's P/E ratio is -0.04. In terms of profitability, PFE's ROE is +0.05%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, PFE is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for PFE.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
PFE vs SCLXW Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, SCLXW has a market cap of 7.8M. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while SCLXW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas SCLXW's P/E ratio is N/A. In terms of profitability, PFE's ROE is +0.05%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, PFE is more volatile compared to SCLXW. This indicates higher risk in terms of short-term price fluctuations for PFE.Check SCLXW's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
PFE vs BDSIW Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, PFE's ROE is +0.05%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, PFE is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for PFE.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
PFE vs CRXT Comparison November 2026
Pfizer Inc. (NYSE: PFE) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PFE stands at 164.7B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, PFE is priced at $28.89 on the NYSE, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PFE currently has a P/E ratio of 9.47, whereas CRXT's P/E ratio is -0.02. In terms of profitability, PFE's ROE is +0.05%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, PFE is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for PFE.Check CRXT's competition here